Table 1.
Variables of the patients who completed the treatment.
| Pretreatment | 4 months | Pretreatment | 12 months | Pretreatment | 18 months | Pretreatment | 24 months | |
|---|---|---|---|---|---|---|---|---|
| Doxycycline 4 weeks | ||||||||
|
| ||||||||
| MF-positive individuals/all (%) | 12/12 (100%) | 9/12 (75%) | 8/8 (100%) | 0/8 (0%) | 5/5 (100%) | 0/5 (0%) | 6/6 (100%) | 3/6 (50%) |
| Comparison to Rifampicin plus Doxycycline § | P = 1.0 | P = .007 | P = .044 | P = .262 | ||||
| Comparison to Placebo § | P = .515 | P = .001 | P = .008 | P = .2 | ||||
|
| ||||||||
| Microfilaraemia | ||||||||
| Median (25th–75th percentile) | 523 (154–1013) | 307 (12–1068) | 523 (227–1006) | 0 | 1100 (372–2010) | 0 | 667 (193–838) | 12 (0–49) |
| Comparison between time points* | P = .388 | P = .012 | P = .043 | P = .028 | ||||
| Comparison to Rifampicin plus Doxycycline # | P = .378 | P = .954 | P = .008 | P = .039 | P = .25 | |||
| Comparison to Placebo # | P = .007 | P = .072 | P = .001 | P = .007 | P = .018 | |||
|
| ||||||||
| Wolbachia load/Mf | ||||||||
| Median (25th–75th percentile) | 167 (71–238) | 11 (4–24) | ||||||
| Comparison between time points* | P = .002 | |||||||
| Comparison to Rifampicin plus Doxycycline # | P = .626 | P = .326 | ||||||
| Comparison to Placebo # | P = .31 | P = .003 | ||||||
|
| ||||||||
| Antigenaemia | ||||||||
| Median (25th–75th percentile) |
14500 (9421–19162) |
20574 (18369–29241) |
16459 (10141–17843) |
22854 (11341–17784) |
11341 (9108–16776) |
17625 (9711–118594) |
13840 (9901–18283) |
28065 (15442–49163) |
| Comparison between time points* | P = .158 | P = .237 | P = .173 | P = .075 | ||||
| Comparison to Rifampicin plus Doxycycline # | P = .71 | P = .828 | P = .362 | P = 1.0 | P = .512 | |||
| Comparison to Placebo # | P = .14 | P = .8 | P = .57 | P = .302 | P = 1.0 | |||
|
| ||||||||
| FDS-positive individuals/all (%) | 10/10 (100%) | 2/10 (20%) | 5/5 (100%) | 0/5 (0%) | 4/4 (100%) | 1/4 (25%) | ||
| Comparison to Rifampicin plus Doxycycline § | P = .429 | P = .09 | P = .101 | P = .569 | ||||
| Comparison to Placebo § | P = .317 | P = .007 | P = .008 | P = .143 | ||||
|
| ||||||||
| No. of FDS | ||||||||
| Median (25th–75th percentile) | 1.0 (1–3.25) | 0 (0–0.25) | 2.0 (0.5–5) | 0 | 1.0 (0.25–1.75) | 0 | ||
| Comparison between time points* | P = .006 | P = .068 | P = .564 | |||||
| Comparison to Rifampicin plus Doxycycline # | P = .796 | P = .081 | P = .065 | P = .555 | ||||
| Comparison to Placebo # | P = .824 | P = .003 | P = .006 | P = .178 | ||||
|
| ||||||||
| Rifampicin plus Doxycycline 2 weeks | ||||||||
|
| ||||||||
| MF-positive individuals/all (%) | 12/12 (100%) | 10/12 (83%) | 13/13 (100%) | 8/13 (62%) | 12/12 (100%) | 7/12 (58%) | 13/13 (100%) | 11/13 (85%) |
| Comparison to Placebo $ | P = 1.0 | P = .249 | P = .245 | P = 1.0 | ||||
|
| ||||||||
| Microfilaraemia | ||||||||
| Median (25th–75th percentile) | 392 (122–460) | 394 (39–703) | 413 (109–465) | 26 (0–133) | 392 (183–468) | 13 (0–64) | 371 (130–465) | 17 (1–290) |
| Comparison between time points* | P = .695 | P = .003 | P = .002 | P = .004 | ||||
| Comparison to Placebo # | P < .001 | P = .058 | P = .015 | P = .019 | P = .031 | |||
|
| ||||||||
| Wolbachia load/Mf | ||||||||
| Median (25th–75th percentile) | 121 (95–200) | 18 (7–52) | ||||||
| Comparison between time points* | P = .034 | |||||||
| Comparison to Placebo # | P = .537 | P = .015 | ||||||
|
| ||||||||
| Antigenaemia | ||||||||
| Median (25th–75th percentile) |
15379 (10154–21680) |
23193 (19514–29162) |
15942 (10356–21680) |
19928 (17305–22719) |
13063 (10186–21852) |
19480 (6432–28276) |
17095 (10247–22273) |
41933 (18834–51020) |
| Comparison between time points* | P = .046 | P = .196 | P = .508 | P = .015 | ||||
| Comparison to Placebo # | P = .084 | P = .606 | P = .034 | P = .091 | P = .808 | |||
|
| ||||||||
| FDS-positive individuals/all (%) | 13/13 (100%) | 8/13 (62%) | 10/10 (100%) | 5/10 (50%) | 12/12 (100%) | 7/12 (58%) | ||
| Comparison to Placebo § | P = .056 | P = .249 | P = .221 | P = .245 | ||||
|
| ||||||||
| No. of FDS | ||||||||
| Median (25th–75th percentile) | 1.0 (1–1.5) | 1.0 (0–1) | 1.0 (1–2) | 0.5 (0–1) | 1.0 (1–2) | 1.0 (0–2) | ||
| Comparison between time points* | P = .034 | P = .011 | P = .014 | |||||
| Comparison to Placebo # | P = .936 | P = .019 | P = .103 | P = .162 | ||||
|
| ||||||||
| Placebo matching Doxycycline 4 weeks | ||||||||
|
| ||||||||
| MF-positive individuals/all (%) | 5/5 (100%) | 5/5 (100%) | 5/5 (100%) | 5/5 (100%) | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) |
|
| ||||||||
| Microfilaraemia | ||||||||
| Median (25th–75th percentile) | 2380 (1230–3680) | 2585 (412–3738) | 2810 (1970–3820) | 283 (105–358) | 1595 (513–4008) | 451 (82–1910) | 1790 (503–4115) | 605 (164–1194) |
| Comparison between time points* | P = .686 | P = .043 | P = .273 | P = .273 | ||||
|
| ||||||||
| Wolbachia load/Mf | ||||||||
| Median (25th–75th percentile) | 133 (85–164) | 358 (100–879) | ||||||
| Comparison between time points* | 0.138 | |||||||
|
| ||||||||
| Antigenaemia | ||||||||
| Median (25th–75th percentile) |
12616 (10398–97319) |
21861 (18614–26987) |
12616 (10345–58134) |
27747 (26039–34228) |
97319 | 28653 | 48995 (10318–98789) |
30902 (7541–76947) |
| Comparison between time points* | P = .866 | P = .5 | P = .285 | P = .465 | ||||
|
| ||||||||
| FDS-positive individuals/all (%) | 3/5 (60%) | 5/5 (100%) | 2/4 (50%) | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) | ||
|
| ||||||||
| No. of FDS | ||||||||
| Median (25th–75th percentile) | 3.0 (0–4) | 3.0 (1–4.5) | 0.5 (0–2.5) | 1.0 (1–1.75) | 1.5 (0.25–2.75) | 1.5 (1–2.75) | ||
| Comparison between time points* | P = .083 | P = .785 | P = .564 | |||||
§Fisher's exact-test.
*Wilcoxon-signed-rank-test.
#Mann-Whitney-U-test.